PPL Electric customers will see their monthly bills increase by about $6.48 for typical residential users starting July 1, 2026, after the Pennsylvania Public Utility Commission approved a rate settlement. This is the first distribution rate increase in eight years for the company, which serves 1.5 million homes and businesses. The additional revenue will fund infrastructure improvements, vegetation management, and smart grid technology, while also expanding assistance programs for low-income customers.

The iShares MSCI World ETF (URTH) is navigating a complex June, facing three major catalysts: a semi-annual dividend increase, a Federal Reserve meeting with a likely rate pause, and new US tariffs on patented pharmaceuticals. These events, especially the Fed's stance on interest rates impacting tech-heavy holdings and the tariffs affecting the healthcare sector, could significantly influence the ETF's performance despite its recent all-time high. Investors are evaluating the potential for price action given these converging factors.

Bell Textron has laid off 285 employees across its facilities in Fort Worth, Amarillo, and Wichita, Kansas. The company attributes these cuts to the need to align with market realities and long-term positioning, specifically in relation to a major aircraft project for the U.S. Army.

Shares of Western Alliance Bancorporation (WAL) and Republic Bancorp (RBCAA) surged 3.6% after the broader financial sector rallied. Regional banks are experiencing a widening of net interest margins due to deposit costs rolling over and sustained loan yields, a trend benefiting from a "higher-for-longer" interest rate environment. This follows a period where regional bank stocks had been under pressure, with Western Alliance Bancorporation down 5.5% year-to-date prior to this rebound.

Controladora Vuela Compañía de Aviación (Volaris) has released May traffic and load factor data showing continued growth and an improved consolidated load factor. The airline reported a year-over-year increase in its consolidated load factor and approximately 4.9% growth in overall traffic, driven by sustained international demand. Volaris's Mexico-listed shares also saw a modest gain of 0.95% during a session where the broader Mexican equity market softened, indicating active trading and investor interest in the low-cost carrier.

Morgan Stanley has upgraded Celsius Holdings (NASDAQ:CELH) to an Overweight rating with a $55.00 price target, citing an attractive risk-reward profile, strong Alani momentum, and anticipated brand Celsius improvement. This upgrade comes despite the stock trading near its 52-week low, with InvestingPro analysis suggesting it is undervalued. The firm expects short-term choppiness in scanner trends but forecasts improved growth for Celsius this summer, supported by strong Q1 2026 financial results and continued analyst optimism.

WD-40 Company announced several executive leadership appointments as part of a planned organizational transition. Patricia Olsem will become chief strategy and innovation officer and Claudia Fenske will be chief brand and marketing officer, with both transitioning to their new roles in fiscal year 2027. Sara Hyzer will be appointed president, Americas division, and Nicholas Giordano will be named vice president, corporate controller, and chief accounting officer effective June 29, 2026.

Littelfuse, Inc. (NASDAQ: LFUS) has filed a Form 144 indicating a proposed sale of Common stock with an effective date of June 3, 2026. The filing also details several restricted stock vesting entries from April 2021. While the Form 144 signals an intent to sell, specific sale amounts and final transaction details are not fully disclosed in this document.

This article details a Form 144 SEC filing by SharkNinja, Inc. (SN). The filing indicates a proposed sale of 2,200 shares of common stock with an aggregate market value of $268,587.00, acquired on March 7, 2025. The document highlights the neutral impact and sentiment of this particular SEC filing.

UroGen Pharma and Teva Pharmaceuticals have settled their patent infringement lawsuit over UroGen's urinary cancer drug. The settlement grants Teva an exclusive license to sell its generic version of the drug starting in September 2030, provided it receives FDA approval. This agreement preserves nearly all of UroGen's patent protection period, which is set to expire in 2031.